CAÁP CÖÙU CÔN HEN PHEÁ QUAÛN
BS CK II Nguyễn ThịTân Xuân
Khoa Hô Hấp BV ChợRẫy
G
IN
A
G
IN
A
lobal
itiative for
sthma
lobal
itiative for
sthma
Chieán löôïc toaøn caàu ñoái vôùi Hen :
Ñieàu trò vaø phoøng ngöøa
Chieán löôïc toaøn caàu ñoái vôùi Hen :
Ñieàu trò vaø phoøng ngöøa
1995
2002
2004
2006
1995
2002
2004
2006
Revised 2006
Revised 2006
Chie
Chieáán
nl
lö
öô
ôïïc
cñ
ñie
ieààu
utrò
trò
Ñ
Ñie
ieààu
utrò
trò ñ
ñe
eååñ
ña
aïït
tmu
muïïc
cñí
ñích
ch kie
kieååm
msoa
soaùùt
t
to
toáát
t”
”
GINA 2006: MU
GINA 2006: MUÏÏC
C ÑÍ
ÑÍCH CU
CH CUÛÛA
A Ñ
ÑIE
IEÀÀU TRÒ
U TRÒ
Hen pheá quaûn coù theå ñöôïc kieåm soaùt moät
caùch hieäu quaû treân moät soá beänh nhaân
… baèng caùch giaûm hieän töôïng vieâm cuõng nhö
laøm daõn caùc pheá quaûn
Reliever: Rapid-acting inhaled β
2
-agonist prn
Controller:
Daily inhaled
corticosteroid
Controller:
Daily inhaled
corticosteroid
plus
Daily long-
acting inhaled
β
2
-agonist
Controller:
Daily inhaled
corticosteroid
plus
Daily long –
acting inhaled
β
2
-agonist
plus (if needed)
When
asthma is
controlled,
reduce
therapy
Monitor
STEP 1:
Intermittent
STEP 2:
Mild Persistent
STEP 4:
Severe
Persistent
Outcome: Asthma Control
Outcome: Best
Possible Results
Controller:
None
–Theophylline-SR
–Leukotriene
–Long-acting
inhaled β
2
-agonist
–Oral corticosteroid
STEP 3:
Moderate
Persistent
Step down
GINA 2003:
Phaùc ñoà ñieàu trò Hen ôû ngöôøi lôùn
GINA
GINA 2003
2003
3
3
2
2
1
1